In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Quest Diagnostics to co-promote Cytyc's ThinPrep Pap Test

Executive Summary

Cytyc and Quest Diagnostics (provider of clinical testing information and services) will combine sales and marketing resources to promote Cytyc's ThinPrep Pap Test--a screen for cervical cancer--to payers, physicians, and patients in the US. In exchange, Quest will receive a warrant to purchase 150,000 shares of Cytyc common stock at $61 per share, for a $915,000 equity investment.
Deal Industry
  • Biotechnology
  • Laboratory Testing Services
  • In Vitro Diagnostics
    • Cytology
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Equity
    • Marketing (Licensing)

Related Companies